Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Horsholm, Denmark, with an office in Cary, North Carolina
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Envarsus | Tacrolimus | 2015-07-10 | 2024-2028 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use